US EditionPublished • loading... • Updated
Lilly to build $3 billion Dutch plant to boost weight-loss pill production
The $3 billion plant will create 500 permanent jobs and boost production of oral medicines including the weight-loss drug orforglipron by 2030, Eli Lilly said.
- On Nov 3, 2025, Eli Lilly said it will build a $3 billion plant at Leiden Bio Science Park, Katwijk, to expand capacity for orforglipron and other oral medicines.
- To scale supply, Lilly has spent billions recently to boost orforglipron production as it proceeds with European regulatory submissions later this year and aims to meet growing demand.
- The plant will create 500 skilled manufacturing jobs and about 1,500 construction jobs, producing oral medicines for diabetes, obesity, cancer and chronic diseases including cardiometabolism, neurology, oncology, immunology.
- Construction is expected to start next year and the first medicines are expected to roll off the production line by 2030, officials said, boosting innovation and supporting Leiden after a major company closure.
- As an outlier in 2025 investment patterns, Eli Lilly's plan arrives amid debate over permits and infrastructure in the Netherlands, according to officials and experts.
Insights by Ground AI
18 Articles
18 Articles
At a time when many companies are considering leaving, American pharmaceutical company Eli Lilly is establishing itself in the Netherlands.
·Netherlands
Read Full Article
$3 Billion Netherlands Plant Part of Lilly’s Global Weight-Loss Push
Source: (PHOTO: WIBC) INDIANAPOLIS — Lilly to Build $3 Billion Plant in the Netherlands, Expanding Weight-Loss Pill Production Indianapolis-based drugmaker Lilly announced Monday it will build a $3 billion manufacturing plant in the Netherlands to increase production of its experimental weight-loss pill, orforglipron, along with other oral medicines. The move is part of Lilly’s ongoing global push to scale up production ahead of regulatory submi…
Coverage Details
Total News Sources18
Leaning Left3Leaning Right2Center4Last UpdatedBias Distribution45% Center
Bias Distribution
- 45% of the sources are Center
45% Center
L 33%
C 45%
R 22%
Factuality
To view factuality data please Upgrade to Premium
